Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

OBJECTIVE: Intra-tumoral heterogeneity of (18)F‐fluorodeoxyglucose ((18)F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positive b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Guang, You, Shuhui, Xie, Yizhao, Gu, Bingxin, Liu, Cheng, Hu, Xichun, Song, Shaoli, wang, Biyun, Yang, Zhongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510219/
https://www.ncbi.nlm.nih.gov/pubmed/37726862
http://dx.doi.org/10.1186/s40644-023-00608-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510219/
https://www.ncbi.nlm.nih.gov/pubmed/37726862
http://dx.doi.org/10.1186/s40644-023-00608-0

Ejemplares similares